CONFIDENTIAL SAP Version: 3.0 Effective Date: 09DEC2020 Page 14 of 27 The following events will be tabulated by SOC and PT. Summaries will be sorted by decreasing frequency of PT within SOC which is sorted alphabetically. • TEAEs by SOC and PT • TEAEs b y PT frequency only • Treatment -emergent SAEs • Treatment -related AEs o Durvaluma b related o Tremelimumab related o Vaccine related • Treatment -related SAEs • TEAEs leading to treatment ( durval umab, tremelimumab, and/ or vaccine ) discontinuation o Durvalumab discontinuation o Tremelimumab discontinuation o Vaccine discontinuation • DLTs A summary of TEAEs by SOC, PT and maximum severity, sorted by decreasing frequency of PT within SOC which is sorted alphabetically, will also be provided for: • TEAEs • TEAEs ≥ CTCAE Grade 3 • Treatment related AEs o Durvalumab related o Tremelimumab related o Vaccine related • TRAEs ≥ CTCAE Grade 3 In tabulation by severity grade, • For a given SOC, only the most severe SOC for each subject will be included. • For a given PT, only the most severe PT for each subject will be included. The following listing s will be provided: • All AEs (flag TEAE) Sponsor: Ludwig Institute for Cancer Research. Protocol Number: LUD2014- 012-VAC. CONFIDENTIAL SAP Version: 3.0 Effective Date: 09DEC2020 Page 15 of 27 • DLTs • SAEs • TEAEs leading to study treatment discontinuation • TEAEs leading to study drug (durval umab or tremelimumab) dose modifications • Death s in the AE reporting period 9.1.2 Adverse Events of Special Interest (AESIs) AESIs will not be separately presented in this analysis. 9.2 Clinical Laboratory Data Clinical Laboratory data (chemistry, hematology, coagulation, and urinalysis) will be collected as specified in the study flowchart in section 3.2 of the protocol.